Make-vs-Buy Strategy & RFP Process for Clinical Development Operations 2026

Published on 15/11/2025

Building the Right Sourcing Model and Running a Rock-Solid RFP for Clinical Operations

Strategic Foundations: When to Build In-House and When to Buy

High-performing sponsors in the USA, UK, and EU treat sourcing as a strategic capability, not a tactical purchase. A make-vs-buy decision frames how you will deliver clinical development services across study phases, therapeutic areas, and geographies—balancing speed, cost, quality, compliance, and flexibility. The “make” option favors internal teams for core competencies, tight control of intellectual property, and differentiated know-how (e.g., first-in-class assets, complex endpoints, or novel decentralized models). The “buy”

option favors specialized vendors and contract research organizations (CROs) to access scale, niche expertise (e.g., imaging, central labs, IRT, eCOA), and global reach, especially where internal capability would be slow or expensive to stand up.

Regulatory expectations also shape the choice. Even when you “buy,” you cannot outsource accountability. Agencies expect the sponsor to maintain oversight aligned to ICH E6(R3) principles of quality by design, risk-based management, and proportionate monitoring; to comply with FDA regulations (including data integrity and computer systems controls under 21 CFR); and to align with EMA and EU-CTR expectations for sponsor oversight across vendors and subcontractors. Global programs must further consider guidance from PMDA, TGA, and WHO where relevant to multinational studies.

Decision Drivers and Analytical Lens

Strategic criticality: Core activities that differentiate your program (e.g., rare-disease recruitment tactics, complex biomarker analytics) favor “make.”
Total cost of ownership (TCO): Include hidden costs—transition, oversight, training, validation, rework, audit findings, remediation, and change orders.
Time-to-capability: If internal build would delay milestones, a “buy” path with a proven partner may de-risk timelines.
Risk and compliance posture: Consider data integrity (ALCOA+), patient safety, privacy, and inspection exposure across jurisdictions.
Scalability and elasticity: Future pipeline surges or geographic expansion may argue for a hybrid model or master service agreements (MSAs).

Leading organizations often select a hybrid model: keep high-impact scientific leadership and quality governance in-house while outsourcing operational execution to vetted partners. This ensures control over design decisions while leveraging external capacity for speed and cost efficiency.

Operating Models: From In-House to Strategic Partnerships

Beyond the binary “make or buy,” sponsors should define the operating model that best aligns with portfolio needs. Common archetypes include functionally outsourced services (e.g., central monitoring, medical writing), full-service CROs accountable for end-to-end study delivery, preferred provider panels for competitive tension, and build-operate-transfer (BOT) constructs where a vendor incubates a capability and transitions it back to the sponsor after maturity. Each model demands a different oversight intensity, RACI structure, and performance framework.

Model Selection Criteria

Complexity and novelty: Highly innovative designs or device-drug combinations benefit from closer sponsor control and embedded SMEs.
Portfolio predictability: Stable pipelines support preferred partnerships; volatile portfolios may retain a flexible panel or project-by-project awards.
Digital ecosystem: Interoperability with EDC, CTMS, safety databases, and eSource platforms requires defined interfaces and validated integrations.

Irrespective of model, sponsors must uphold documented oversight consistent with EU GCP and FDA Clinical Trials expectations—evidence trails that demonstrate governance bodies met, risks were reviewed, KPIs and quality indicators were tracked, and CAPA was effective.

Designing a Compliant and Competitive RFP Process

A well-designed request for proposal (RFP) translates strategy into executable vendor obligations. It sets transparent evaluation criteria, mitigates bias, and anticipates regulatory scrutiny. The RFP should articulate scientific context, protocol synopsis or draft, endpoints and estimands, geographies, target timelines, data standards, technology stack requirements, and responsibilities split across sponsor and vendor. It should embed expectations for data integrity (ALCOA+), cybersecurity posture, patient-privacy compliance, and computer system validation/assurance aligned to FDA guidance and ICH Quality principles.

RFP Pack Essentials

Scope of Services Matrix: Detailed WBS covering study start-up, conduct, closeout, DM, biostats, pharmacovigilance, medical monitoring, labs, imaging, IRT, eCOA.
Assumptions and Inputs: Enrollment curves, site mix, monitoring approach (RBQM/RBM), source verification strategy, DCT elements, translation needs.
Standards and Controls: Data formats (CDISC), EDC/CTMS interfaces, audit trail requirements, role-based access, and change control workflows.
Quality & Compliance: QMS alignment, SOP mapping, inspection support, deviation/CAPA process, and risk management plan expectations.
Commercial Framework: Pricing templates, rate cards, milestone definitions, pass-through handling, and change-order governance.

Ask vendors to submit detailed risk registers, resource plans by role/FTE, country startup strategies, site engagement tactics, and technology validation plans. Require examples of inspection outcomes, client references, and performance against prior SLAs. This enables an apples-to-apples comparison across proposals and surfaces execution risk early.

Fair Competition and Ethics in Vendor Engagement

Procurement integrity is essential for credibility and audit readiness. Define clear contact rules, timelines, and Q&A channels; maintain an audit trail of all communications; and ensure equal access to clarifications. Guard against scope creep during the RFP by freezing baselines and capturing changes in addenda shared with all bidders. Require conflict-of-interest declarations from evaluators and vendors. Document every decision: shortlists, score rationales, and negotiation outcomes—these records often become critical during FDA or MHRA inspections and sponsor audits.

Evaluation Governance

Cross-functional panel: Clinical operations, QA, biostats, data management, safety, regulatory, finance, legal, and IT security participate.
Weighted scoring model: Technical approach, team experience, quality and compliance, delivery risk, and commercial competitiveness.
Calibration and consistency: Hold scoring huddles to align interpretations; record dissent and final consensus decisions.

Transparency builds trust with bidders and withstands regulatory review. The process must be accessible, consistent, and defensible, reflecting principles promoted across EMA, ICH, and WHO frameworks for ethical research conduct.

From Proposal to Contract: SOW Precision and Quality Agreements

Once a preferred bidder is selected, translate the winning solution into a contract that eliminates ambiguity. The statement of work (SOW) should enumerate deliverables, acceptance criteria, milestone definitions, reporting cadences, and documentation sets (e.g., study plans, TMF contributions, validation packages). The quality agreement should outline QMS alignment, deviation and CAPA processes, audit/inspection support, data integrity controls, cybersecurity expectations, and roles in risk management and vendor sub-oversight.

Commercial and Risk Controls

Payment tied to outcomes: Stage payments on objective achievements, not effort-hours alone.
Change-order discipline: Define materiality thresholds, approval paths, and impact assessments on scope, budget, and timeline.
Liability and IP: Clarify ownership of data, code, and documentation; define indemnities and limits based on risk profile.

Include obligations for data standards, audit trail retention, and role-based access controls in systems that may fall under FDA Part 11 or EU Annex 11 interpretations. Align with ICH efficacy and quality expectations, ensuring that vendor processes integrate into the sponsor’s QMS and document workflows.

Key Performance Indicators, SLAs, and Issue Management

Performance management transforms contracts into results. Establish a KPI framework that measures both operational delivery (e.g., start-up cycle times, data entry timeliness, query aging, monitoring visit execution, protocol deviation rates) and quality indicators (e.g., eTMF health scores, audit/inspection outcomes, data integrity exceptions, PV case timelines). Service-level agreements (SLAs) set minimum performance baselines and response times while key risk indicators (KRIs) provide early-warning signals for proactive intervention.

Governance Rhythm

Daily/weekly operations: Study huddles reviewing burn-down charts, risks, and mitigations; joint dashboards with access controls.
Monthly reviews: Portfolio-level scorecards, corrective action progress, and trend analysis across countries and vendors.
Quarterly executive steering: Strategic topics, capacity planning, pricing re-openers, innovation roadmaps, and risk sharing.

Define an issue escalation ladder with time-bound triggers and RACI clarity. For significant nonconformances, require formal CAPA with effectiveness checks. Ensure that every material issue feeds back into risk registers and is visible to governance bodies. This evidence becomes part of your inspection narrative before FDA, EMA, and national competent authorities.

Data Integrity, System Access, and Validation/Assurance

When activities are outsourced, system ownership may be distributed but accountability is not. Sponsors must approve role-based access designs, review audit trails, and ensure GxP systems undergo appropriate validation or computer software assurance. Define requirements based on risk: criticality of the function (e.g., EDC, IRT, eCOA, safety database), data life-cycle controls, and cybersecurity hygiene. Require vendors to document configuration control, change management, backup/restore, and disaster recovery testing.

Control Architecture

Access governance: Joiner-mover-leaver processes, periodic access recertification, and segregation of duties.
Audit trail review: Risk-based sampling, exception reporting, and linkage to data-management and QA oversight.
Validation/assurance: Risk-based testing, traceability, vendor documentation leverage, and sponsor acceptance criteria.

Align practices to the spirit of ICH multidisciplinary guidance, local data-protection laws, and expectations of agencies such as PMDA and TGA. Periodic independent audits of vendor-managed systems should corroborate continuous control effectiveness.

Risk-Based Oversight and Inspection Readiness

Risk-based quality management (RBQM) is central to ICH E6(R3) thinking and must be embedded across outsourced work. Calibrate oversight to what matters for patient safety, data reliability, and rights. Tailor monitoring strategies (including centralized and remote methods), calibrate SDV/SDS review levels, and map critical data and processes to targeted checks. Your oversight plan should describe how the sponsor evaluates vendor risk, integrates indicators into study risk controls, and conducts independent QA audits.

Evidence That Stands Up in an Inspection

Structured oversight plan: Clear inputs, roles, frequency, tools, and documentation outputs.
Traceable decisions: Risk logs, governance minutes, CAPA records, and KPI trend analyses with actions taken.
TMF completeness: Contracts, SOWs, quality agreements, plans, communications, training, and validation evidence placed correctly.

Train teams on inspection conduct and storyboarding. Ensure that vendor personnel understand sponsor expectations and can retrieve evidence quickly. Harmonize narratives across sponsor and vendor to avoid inconsistencies that can raise regulator concerns in the US, UK, and EU.

Sustainable Commercial Models and Negotiation Levers

Commercial structure influences behavior. Balance fixed-fee components for predictable tasks with unit-based pricing for variable volumes and milestone-based payments for outcomes. Consider incentives for cycle-time improvements, quality thresholds, and innovation pilots. Risk-sharing models—such as gainshare tied to startup speed or data-quality KPIs—can align interests while protecting patient safety and data integrity.

Negotiation Guardrails

Baseline clarity: Lock in scope, assumptions, and data standards before pricing; avoid ambiguity that drives change orders.
Benchmarking: Use historicals and industry references to calibrate rates and productivity assumptions.
Exit options: Define step-in rights, transition assistance, and knowledge-transfer deliverables up front.

Ensure the commercial framework reinforces compliance: penalties for repeated quality failures, requirements for prompt remediation, and obligations to support audits and inspections by authorities including the FDA and EMA.

Implementation Roadmap: From Business Case to First Patient In

A practical roadmap links strategy to execution. Start with a business case defining value drivers, risk appetite, and target operating model. Build a sourcing plan mapping work packages to the chosen model. Prepare the RFP pack, set up the governance calendar, and pre-define the KPI/KRI framework and dashboards. Run the competitive process to a disciplined timeline; debrief all bidders to sustain long-term market trust. Post-award, launch an integrated mobilization plan: team onboarding, SOP alignment, tool access provisioning, data standards confirmation, and validation/assurance acceptance.

Mobilization Checklist

Approved oversight plan with RBQM linkages and documented roles/responsibilities.
Signed SOW, quality agreement, data-processing terms, and cybersecurity clauses.
System access granted via role-based controls; validation evidence reviewed and accepted.
Baseline dashboards live; KPIs/KRIs measured from Day 1; escalation ladder tested.
TMF filing plan executed; communications cadence aligned with governance.

Within the first 90 days, conduct a joint health-check to validate that processes are stable, risks are under control, and teams are inspection-ready. Use lessons learned to refine the model for subsequent studies, creating a repeatable, compliant engine for delivery across the portfolio.